论文部分内容阅读
患者只需取一滴血,即可用于癌症病情监测和治疗效果评价,为指导肿瘤治疗提供辅助依据——11月17日,清华大学宣布,由生命科学学院罗永章教授研究组在国际上首次发现热休克蛋白90α(Hsp90α)为一个全新的肿瘤标志物,自主研发的Hsp90α定量检测试剂盒已通过临床试验验证,获得国家第三类(最高类别)医疗器械证书,并通过欧盟认证。我国拥有完全自主知识产权的首个肿瘤标志物据统计,我国每年新发癌症病例312万,因癌症死亡270万人。据世界卫生组织预测,2020年全球癌症新发病例将达到2000万,因癌症死亡1200万人。寻找
Patients only need to take a drop of blood, which can be used for cancer condition monitoring and therapeutic effect evaluation, and provide an auxiliary basis for guiding cancer treatment. On November 17, Tsinghua University announced that the research group of Professor Luo Yongzhang from the School of Life Sciences has discovered heat for the first time in the world. Shock protein 90α (Hsp90α) is a brand-new tumor marker. The independently developed Hsp90α quantitative detection kit has passed clinical trials and has won the national third-class (highest category) medical device certificate, and has passed the EU certification. China’s first tumor marker with completely independent intellectual property rights According to statistics, China has 3.12 million new cases of cancer every year, and 2.7 million people died of cancer. According to the prediction of the World Health Organization, 2020, the number of new cancer cases in the world will reach 20 million, and 12 million people will die from cancer. Look for